Biotech

Gilead Sciences GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences is arguably the most interesting success story in the world of biotech at the moment. However, there has been a major issue helping to keep their stock down. That issue is competition. Nonetheless, I’m a firm believer that this stock is likely to move in a big way; and that we’re seeing the start of it as we speak. I’ve said it time and time again; and my view hasn’t changed in the slightest… GILD is incredibly undervalued. However, that undervaluation isn’t likely to last forever. Today, we’ll talk about how Gilead Sciences eased fears revolving around competition, what we’re seeing in the market today, and what we can expect to see moving forward. So, let’s get right to it…

Gilead Sciences Shows That Fears Are Unwarranted

For the most part, this year has been the year of fear for GILD investors; and for good reason. Earlier this year, AbbVie, Inc. (NYSE: ABBV) moved in to take a slice of the Gilead Sciences hepatitis C treatment pie by releasing their own treatment for the ailment. Unfortunately for Gilead Sciences, the AbbVie treatment was picked up by several insurance carriers based on the lower price; leading to concerns that GILD would start to see declines in the value of its hepatitis C franchise. However, Gilead Sciences may have put those concerns to rest.

Recently, GILD released their earnings report for the second quarter; and as I predicted, the company blew away all expectations! While analysts expected the company to report earnings per share of $2.71, the company actually reported $3.15. This showed investors that even with stiff competition in the HCV space, they are still more than capable of generating earnings.

What We’ve Seen In The Market From GILD

Since the earnings report, Gilead Sciences has been on a relatively bullish run; and today, the stock has climbed to resistance and is working to break through. Currently (12:17), GILD is trading at $119.22; just pennies away from resistance. As soon as the stock climbs above $119.60, I’m expecting for investors to get excited; pushing GILD to new heights.

What We Can Expect To See Moving Forward

Moving forward, I’ve got overwhelmingly positive opinions of Gilead Sciences in both the short and long term. The reality is that the company has proven that even in the face of strong competition, they are capable of generating solid revenues and earnings for their investors. Not to mention, the recent regulatory approval in Japan is likely to lead to strong sales figures with regard to Harvoni; the company’s hepatitis C treatment. So, in the short run, we can expect for investors to work to push this stock up to a valuation it deserves. In the long run, we can expect to see that deserved valuation rise as Harvoni continues to climb!

What Do You Think?

Where do you think GILD is headed and why? Let us know your opinion in the comments below!

Image Credit

MannKind Stock Headquarters

MannKind Corporation (NASDAQ: MNKD)

For me, one of the most interesting stocks in biotech is MannKind Corporation. That’s because throughout the past year, MNKD has been the stage for one of the biggest battles between the bulls and the bears that I’ve seen in quite some time. More importantly, there’s a level of validity to each side. So today, we’ll talk about the different views of MannKind stock and discuss whether the bear or the bull is likely to win this battle in the long run. So, let’s get right to it…

Bears Have Quite The Argument

First and foremost, let’s focus on what the bears have to say. When we break the bearish argument down to the bottom line, what we come up with is Afrezza sales. For those of you who haven’t been following MNKD, Afrezza is an inhaled insulin produced by MannKind that was expected to hit the market running. However, as the bears will so gladly point out, it has done anything but. The bottom line is that Afrezza sales are incredibly weak; and have been since the beginning of the pre-launch. Week after week, we’ve seen prescription numbers, and week after week, those numbers have proved to be disappointing at the least. So, the bears argue that if MannKind can’t make sales in the pre-launch, it’s not very likely that they will be able to make sales when they actually do launch sales campaigns around the inhaled insulin. While I will say that I tend to be on the bullish side of the argument, there’s absolutely no denying that the bears have a point here. However, I think that there’s a bit more to the story that the bears aren’t realizing; and that story is a long run one.

Bulls Also Have An Incredibly Valid MNKD Argument

On the other hand, the bulls remain strong; and are doing everything they can to get the stock moving in the positive direction. However, unlike the bears, the bulls aren’t focusing on the short term. In reality, most bulls couldn’t care less about the poor weekly sales reports as they believe that Afrezza will be a smash hit in the long run. It’s also important to mention that the bull argument with regard to MannKind is multifaceted. Here are the moving pieces…

  • Afrezza Has Seen No Advertising – The first argument that just about any bull will make is that no product tends to get very far without advertising. More importantly, Afrezza is in the pre-launch phase, and hasn’t seen any advertising of its own. Therefore, it’s relatively easy for the bulls to shrug off poor sales reports because they know that advertising could make a big difference; which is likely to happen soon. As a matter of fact, we’ve been hearing for about a month now that the Direct to Consumer phase is just around the corner. All in all, the bulls have faith that Afrezza will be a hit, but they also realize that it’s not going to happen over night.
  • Technosphere Is Also Going To Be A Hit – Another thing that the bulls tend to point out is the technology that made an inhaled insulin possible. That technology is called technosphere; and it just so happens that technosphere is a proprietary technology to MannKind. This technology has the potential to assist in the creation of other inhaled medications that for now, can only be delivered via injections. In the long run, this is also likely to be incredibly profitable.

The Deciding Factor In Both Arguments…Time!

When we break the arguments down to their core, what we find is that the defining factor between both of them is time. The reality is that the bears are focusing on short term results and short term reactions. However, the bulls are focusing on the fact that MannKind is an investment, not a trade, and will take time to realize its true value. The bottom line is…. I don’t think that anyone could argue that in the short term, MannKind isn’t likely to blow its value out of the water. However, I’m also not sure that anyone could pheasibly argue that MannKind isn’t going to prove to be a solid long term investment. The key here is the length of time the investor is willing to wait for a return.

What Do You Think

When it comes to MNKD are you a bear or a bull? Let us know your opinion in the comments below!

Image Credit

Regeneron REGN Stock News

By Cody Miecnikowski

On Tuesday, August 4, before market open, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported its second-quarter 2015 financial results that beat both top and bottom line expectations. The biotech giant, which recently won approval for its cholesterol drug, Praluent, said its profit doubled in its second quarter as sales of Eylea, its eye-disease treatment, surged.

Specifically, the company’s revenue jumped 50% year-over-year to $998.6 million, crushing estimates of $887.8 million. Non-GAAP EPS clocked in at $2.89, also ahead of analyst estimates of $2.77. However, the key focus of the report was sales of Regeneron’s blockbuster eye drug, Eylea. The company produced incredibly strong sales in that respect, posting a 50% year-over-year increase to $933 million. Subsequently, Regeneron raised the full-year 2015 sales forecast for its flagship product from the range of 30% and 35% growth to between 45% and 50% growth compared to 2014.

The company did not provide a forecast for its new cholesterol drug, Praluent, which was developed in partnership with French drugmaker Sanofi. Yet, analysts expect Praluent, approved on July 24, to be the next focus for investors. Specifically, Wall Street expects the drug to hit peak annual sales of more than $5 billion. Regeneron warned that Praluent sales may rise only gradually cautioning, “for next several months, performance cannot be judged upon reported sales.”

As evident from the data above, the earnings report released by Regeneron proved to be incredibly positive. Shares snapped higher in response, increasing 5.55% to $585.02 in the premarket alone. Moreover, the company’s shares rose to a record $605.93 in trading on August 4, aiding in its 41% increase year-to-date.

Nevertheless, some Wall Street analysts have expressed neutral sentiments on Regeneron shares.

In a research report issued on August 4, J.P. Morgan analyst Cory Kasimov reiterated a Hold rating on shares of Regeneron though he did not provide a price target. Kasimov commented, “This morning REGN printed another top- and bottom-line beat. In particular, Eylea boasted an impressive quarter with $655M in US sales (+21% Q/Q, +58% Y/Y), which prompted another bump to 2015 revenue guidance.” Furthermore, “Regeneron tweaked several other guidance line items that should help bottom-line performance for the full year.” Kasimov concludes, “There were incremental pipeline updates in the press release, most notably that the dupilumab Phase 3 trial for in atopic dermatitis has now been fully enrolled.”

Cory Kasimov has rated Regeneron a total of 11 times since February 2014. He has only recommended neutral ratings, earning himself a 0% success rate recommending the stock and a 0% average return per recommendation when measured over a one-year horizon and no benchmark. Overall, he has a 59% success rate recommending stocks and a 13.2% average return per recommendation.

Cory Kasimov

Separately in a research note issued on August 4, Piper Jaffray analyst Edward Tenthoff reiterated a Hold rating on Regeneron while setting a price target of $607. The analyst has rated Regeneron a total of 9 times since July 2010, earning a 100% success rate recommending the stock and a +104.8% average return per recommendation when measured over a one-year horizon and no benchmark.

Edward Tenthoff

Out of 14 analysts polled by TipRanks, 10 analysts are bullish on Regeneron and 4 are neutral. The average 12-month price target for Regeneron is $574.38, marking a (-1.13%) potential downside from where stock is currently trading. On average, the all-analyst consensus for Regeneron is a Moderate Buy.

Image Credit

Biotech Stock News

Lexicon Pharmaceuticals Declines After Yesterday’s Gains

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Lexicon Pharmaceuticals had an incredible day in the market yesterday after releasing top-line data from its phase 3 study of telotristat etiprate. The study looked into the efficacy and tolerability with regard to the medication as a treatment for cancer patients with carcinoid syndrome. Upon the data release, we found out that LXRX met its primary endpoint and will be heading for a new drug application with the FDA. As a result, the stock soared by more than 50% in a single trading session. Unfortunately however, we’re seeing declines today. As a matter of fact, LXRX is currently (1:57) trading at $12.15 per share after a loss of 10.66% so far today. However, I’m not concerned about today’s declines. The reality is that price movement in the market tends to happen through a series of overreactions. Therefore, we’re simply seeing a reaction to yesterday’s gains; bringing the value down to a more sustainable rate.

Synergy pharmaceuticals Is Ready To Climb

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals is a stock that I’ve been watching for quite some time now; and I have to say, it’s one of my favorite stories at the moment. Recently, the company released strong data from its final phase 3 study looking into plecanatide. The data proved to be overwhelmingly positive and the company is now working to move toward a new drug application of their own. I wrote an article earlier today looking into both the technical and fundamental aspects of SGYP and found that this one is gearing up for massive gains. To read it, click here. Synergy Pharmaceuticals is currently (2:01) trading at $8.76 per share after a loss of 12.12% so far today. However, I’m not concerned at all as I think a strong bullish breakout is heading our way!

Regeneron Pharmaceuticals Climbs On Solid Earnings

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron Pharmaceuticals is having a great day in the market today after releasing their second quarter earnings report and blowing away expectations with regard to EPS and revenue. In terms of earnings per share, the company reported $2.12. Revenue came in at $998.6 million. Both earnings and revenue towered above analyst expectations of $1.81 per share and $891 million respectively. The company also increased figures with regard to its full year guidance by 10 percentage points; insinuating massive growth potential. As a result of the positive news, REGN is currently (2:05) trading at $584.53 per share after a gain of 5.46% so far today. With strong earnings and other strong data in the report, I’m expecting to see more growth from this one as we move forward.

Gilead Sciences Stalls…Not For Long!

Gilead Sciences, Inc. (NASDAQ: GILD)

Finally, we have Gilead Sciences; arguably the best success story in the biotech space today. As I’ve mentioned in several previous posts, I believe that GILD is incredibly undervalued; and while we’ve seen growth recently, it has unfortunately stalled today. Currently (2:07), GILD is trading at $119.00 per share after a loss of 0.51% so far today. However, I’m not at all concerned about declines. Gilead’s fundamentals are strong and will likely continue with the upward momentum tomorrow.

Image Credit

Regeneron REGN Stock News

Regeneron Pharmaceuticals Inc (NASDAQ: REGN)

Regeneron Pharmaceuticals stock is having a great day in the market today after releasing its results from the second quarter. Today, we’ll take a look at REGN’s Q2 results, how investors reacted to the news, and what we can expect to see moving forward. So, let’s get right to it…

REGN Tops Q2 Estimates In A Big Way

As mentioned above, Regeneron Pharmaceuticals released their earnings report for the second quarter; and the report was a hit. Here are the details that we saw…

  • Earnings Per Share – In the second quarter, analysts were expecting that Regeneron Pharmaceuticals would report earnings of $1.81. However, the company actually produced earnings in the amount of $2.12 per share; $0.31 ahead of analyst expectations.
  • Top-Line Revenue – Regeneron also produced incredibly strong top-line revenue figures. In the second quarter, REGN produced $998.6 million; coming to $107.6 million ahead of analyst expectations of $891 million.
  • Eylea Sales – The key focus on the earnings report proved to be Eylea sales. The company produced incredibly strong sales in that respect. As a result, they have increased revenue guidance from between a 30% and 35% growth to between 45% and 50% growth over last year.

As you can see from the data above, the earnings report produced by Regeneron Pharmaceuticals proved to be incredibly positive.

How The Market Reacted To The News

As we’ve come to expect any time we see positive news in an earnings report, Regeneron Pharmaceuticals is having a great day in the market today as a result. Currently (12:48), REGN is trading at $587.08 per share after a gain of 5.92% so far today.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see more positive news out of Regeneron Pharmaceuticals. Through their earnings report, they have proved that Eylea is more successful than anyone expected it to be; which will lead to gains in the long run. Also, considering that the company has a strong history of producing better-than-expected earnings, a strong team, and a great plan for growth; I’m expecting more good news in the days, weeks, months and years ahead.

What Do You Think?

Where do you think REGN is headed and why? Let us know in the comments below!

Image Credit

Synergy Pharmaceuticals SGYP Stock Chart

Synergy Pharmaceuticals Inc (NASDAQ: SGYP)

Synergy Pharmaceuticals has been an incredibly interesting stock to watch recently. After releasing positive results from the second phase 3 study of Plecanatide, we recently saw massive gains in the stock. However, since then, we’ve seen ups and downs, but no real, lasting movement in either direction. Today, we’ll take a look at the stock’s chart to see if it gives us any clues. We’ll also take a look at fundamental factors in an effort to determine what we can expect to see moving forward. So, let’s get right to it…

The SGYP Chart Seems Primed For Take-Off!

Looking at the chart above, a few things become incredibly clear. First off, on July 30th, Synergy Pharmaceuticals had an incredible run toward the top. However, since then, we’ve seen choppy movement in both directions. As a result of the movement we’ve seen over the past week, a very familiar shape is starting to make itself apparent in the chart; a flag. Flags are signs for technical traders that a breakout is coming soon. If the flag is right side up, chances are stronger for a bullish breakout than for a bearish breakout; as is the case here. With that said, speaking purely from a technical standpoint, it seems as though SGYP is gearing up for strong gains.

Synergy Pharmaceuticals Is Also Very Strong Fundamentally

While the SGYP chart is insinuating that we can expect to see a breakout some time soon, that’s not the only positive piece of data we have about the stock. As a matter of fact, just about everything I’ve come across from a fundamental standpoint has been positive; and it all surrounds plecanatide…

  1. Primary Endpoint Met – As mentioned above, we recently heard from Synergy Pharmaceuticals that their phase 3 study of plecanatide met its primary endpoint; ultimately proving a statistically significant improvement over the current market leader, linzess.
  2. No Major Side Effects – The study also proved that there were no major side effects and very few minor side effects for patients to worry about. Also, while doctors and scientists may not be concerned about weight gain, patients will be; and plecanatide proved not to come with the weight gain side effect experienced by patients using linzess.
  3. NDA Coming Soon – Upon the release of the data, Synergy Pharmaceuticals’ CEO explained that the next step will be to work with the FDA for the submission of a new drug application; the first in SGYP history. This is likely to prove to be a strong positive catalyst.

So, there you have it, no matter how you look at Synergy Pharmaceuticals things are looking great. While we are seeing declines today, I think that those declines are going to prove to be a great time to get in on gains at a discount.

What Do You Think?

Where do you think SGYP is headed and why? Let us know in the comments below!

Lexicon Pharmaceuticals LXRX Stock News

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Lexicon Pharmaceuticals is having a rough day in the market today. However, I don’t think that the declines are likely to last. The reality is that the company released incredibly positive data with regard to a phase 3 test of an experimental drug yesterday; which will likely prove to be incredibly profitable in the long run. Today, we’ll talk about the data we saw yesterday, why LXRX is declining today, and what we can expect to see moving forward. So, let’s get right to it…

Lexicon Pharmaceuticals Meets Primary Endpoint

Yesterday, Lexicon Pharmaceuticals climbed by more than 50% in a single trading session after announcing that they had met their primary endpoint in Phase 2 clinical testing of telotristat etiprate; an experimental medication designed to treat cancer patients with carcinoid syndrome that is not adequately controlled by the current standard of care. The study compared the affects of telotristat etiprate to the affects of a placebo; proving that their experimental drug is effective in treatment.

What We’re Seeing From LXRX In The Market Today & Way

LXRX is having a tough day in the market today; currently (11:54) trading at $12.66 per share after a loss of 6.91% so far. However, I’m not very concerned about the declines we’re seeing today. As a matter of fact, what we’re seeing today is nothing more than normal market movement. One factor that’s important to remember in situations like this is the fact that price movements in the market tend to happen through a series of overreactions. Therefore, after yesterday’s positive news, the stock got pushed up a bit higher than it should have. As a result, we’re seeing declines today; bringing the value down to a more realistic level. Nonetheless, none of this should be concerning in the least.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see overwhelmingly positive news. As mentioned above the company met its primary endpoint in testing of its experimental drug, telotristat etiprate. Therefore, the next step will be a new drug application with the FDA. When the new drug application is submitted, we can expect to see more massive gains. Also, the treatment being studied could turn out to be the first change to standard of care in more than a decade and a half and prove to be incredibly profitable in the long run. So, if you’re looking to get in on the long run gains, today’s declines may be your opportunity to do so at a discount.

What Do You Think?

Where do you think LXRX is headed and why? Let us know in the comments below!

Image Credit

Biotech Stock News

Nymox Pharmaceutical (NASDAQ:NYMX)

On July 27, 2015 Nymox surged as high as 100% after the company reported positive phase 3 results for its BPH study. BPH stands for benign prostatic hyperplasia, and is characterized by an enlarged prostate gland. This enlarged prostate gland causes problems such as problems of urinating or the need to urinate often.

Both phase 3 trials used Nymox’s drug known as NX-1207 — also known as fexapotide triflutate. Both of these phase 3 trials are extension studies and both were able to produce positive efficacy results for these patients. Both studies met the primary endpoint of being statistically significant over the placebo compound in each trial.

The NX-1207 drug and placebo compound were compared using a measurement score known as the AUA BPH symptom score. About 64% of the patients achieved a statistically significant higher score than those of the placebo patients. What makes these results even more impressive is that these patients only received one injection in a two year period and were able to achieve efficacious results.

With these results on hand Nymox can now talk with both the FDA and EMA — two regulatory authorities — and seek approval from each respective territory. Why on earth did the share price for Nyxom surge 100% in one day? Not only did NX-1207 achieve high efficacy but it did so with limited treatment necessary as compared to standard of care. Current treatments for BPH require a patient to have to take a pill everyday for the rest of their lives.

On the other hand NX-1207 only requires one injection that can last for a few years. Think about what option a patient would like to choose for their treatment? Pay for pills every month from a local pharmacy or go once to a doctors office for single injection. Most likely than not most patients would choose to receive a single injection that would work in the body for several years. There are about 3 million people in the U.S. diagnosed with BPH each year. Therefore the market is huge and Nymox has the ability to capitalize on a pretty big market for this indication.

Galena Biopharma (NASDAQ:GALE)

On July 29, 2015 Galena ended the day up around 5% after it had announced the launch of its new anti-nausea drug known as Zuplenz. Zuplenz is an oral soluble film that helps reduce nausea and vomiting in patients that receive toxic chemotherapy cancer treatment. Although this drug product helps with other toxic cancer treatments as well. As we all know current chemotherapy drugs may or may not clear the cancer but they definitely kill every white blood cell in the body.

This killing of good and bad white blood cells leads to nausea, vomiting, and other complications. More specifically Zuplenz helps with three types of toxic treatments: Chemotherapy-induced nausea and vomiting, Radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting.

Zuplenz is a type of formulation that is similar to a current anti-nausea drug known as ondanestron. Galena states that it will make available two different doses in which patients can take. The company will be able to supply 4 mg and 8 mg of Zuplenz to patients.

What makes this Zuplenz product superior to current therapies? Well for starters Zuplenz is taken as a film that a patient puts in their mouth and then dissolves in 10 seconds or less. No more having to swallow pills for that Nausea. In addition Zuplenz has some additional advantages over other medications as well such as:

  1. No drowsiness seen after taking it
  2. Is created with a fresh peppermint flavor to avoid nasty sour taste
  3. Drug can be taken without the need for water
  4. No nasty aftertaste like other drugs have

It is too early to see how patients and doctors respond to this type of treatment but with the clear advantages Zuplenz provides over current therapy ondanestron it will take a huge chunk of the market. Galena has this marketed drug along with other therapeutic pipeline drug candidates like its breast cancer vaccine Neuvax currently in a phase 3 clinical trial.

Synergy Pharmaceuticals (NASDAQ:SGYP)

On July 30, 2015 Synergy shares closed the day up 5% after the company announced positive results for its phase 3 trial in patients with Chronic Idiopathic Constipation — CIC. This was the second phase 3 study the company had initiated to provide efficacy of its drug compound Plecantide against a placebo. This phase 3 trial recruited 1,337 patients with CIC and were split into different dosing groups.

One group of CIC patients were provided with a lower dose of 3 mg of Plecantide, and the other group of patients were given a higher dose of 6 mg of Plecantide. What made the results of Plecantide so great? Well for starters both the 3 mg and 6 mg of Plecantide were superior to the placebo compound. Matter in fact patients on the drug obtained a 20% durable response rate compared to placebo patients who only obtained an 8% durable response rate.

The only serious adverse event observed in the Synergy drug Plecantide was diarrhea, which was slightly higher than placebo. Despite Plecantide having a slightly higher rate of diarrhea over placebo patients shouldn’t be a huge burden for the company. Synergy’s drug managed to achieve a higher efficacy over its placebo counterpart and a higher rate of diarrhea is not a huge cause for concern from the FDA. Now Synergy will have to meet with the FDA to determine an NDA filing date to attempt to gain regulatory approval for Plecantide in the CIC indication.

Image Credit

Biotech Stock News LXRX SGYP GILD EXEL

Lexicon Pharmaceuticals Climbs On Positive Phase 3 Data

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

Lexicon Pharmaceuticals is today’s biggest gainer in biotech; and for good reason. Early this morning, the company released data from it’s Phase 3 clinical trial, known as TELESTAR. The trial looked into the effectiveness of telotristat etiprate in treating cancer patients that are suffering from carcinoid syndrome for whom standard of care is proving to be ineffective. The next big move for the company from here will be working with the FDA in order to get the treatment to the market. Here’s what Lonnel Coats, CEO of Lexicon Pharmaceuticals had to say about the results of the study…

We are extremely pleased with these top-line results…. Carcinoid syndrome is severely debilitating, preventing many patients from leading active and predictable lives, and unfortunately, a majority of patients will not be adequately controlled over time with the current standard of care. We are committed to working with the FDA to file our first new drug application and to bring this innovative new treatment to patients whose lives are already impacted by the challenges of cancer.”

As a result of the data release, LXRX is currently (1:00) trading at $13.50 per share after a massive gain of 59.95% so far today. However, I don’t think we’ve seen the last of the gains. As the company’s first NDA is filed and telotristat etiprate becomes an approved treatment, the sky really is the limit.

Synergy Pharmaceuticals Continues To Battle The Bears

Synergy Pharmaceuticals (NASDAQ: SGYP)

Synergy Pharmaceuticals isn’t having the best time in the market today as the battle between the bears and the bulls continues on. Unfortunately, short interest is driving the stock down; even though there are plenty of reasons for this one to climb. After all, SGYP did meet their primary endpoint on both of their phase 3 studies of plecanatide and will be heading for a new drug application with the FDA as the next step. With that said, I wouldn’t be surprised if the battle continued to hold the stock in a flat range until we receive more news about the NDA. Nonetheless, I am expecting to see massive growth in the long term; first as the NDA is submitted and another big run upon approval. So, now may be the time to consider jumping in at a discount. Currently (1:04), SGYP is trading at $8.78 per share after a loss of 3.76% so far today.

Gilead Sciences Continues Trending Up

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences has been trading at a discount for quite some time now as the bears continue to push the resistance. Nonetheless, I don’t think that discount is likely to last much longer; especially considering the growth we’ve seen from the stock over the past week. The growth is the result of an easing of concerns that revolved around the company’s dominance of the HCV treatment market as ABBV stepped in to take their piece. Nonetheless, with their recent earnings report, Gilead Sciences proved that they have strength and stability on their side. Also, with the recent regulatory approval in Japan, growth is all but imminent. With that said, if you plan on taking advantage of the GILD discount, you may need to act soon. Currently (1:09), GILD is trading at $118.87 per share after a gain of 0.86% so far today.

Exelixis Sees Gains As Investors Shrug Off Secondary Offering

Exelixis, Inc. (NASDAQ: EXEL)

Exelixis has a relatively interesting story to tell as of late. After seeing massive gains as the result of positive phase 3 data from their most recent clinical study, Exelixis released a secondary offering that caused concerns for investors; leading to declines. However, the stock is growing again as investors shrug off the secondary offering and focus on the company’s core growth potential. With a new drug application just around the corner, strong investor sentiment, and a strong team, this one is likely to see big growth moving forward. Currently (1:13), EXEL is trading at $5.99 per share after a gain of 4.54% so far today.

Image Credit

Gilead Sciences GILD Stock News

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences has been one of my favorite stocks to follow for months now. Ever since I came across the stock, I’ve found the story of success to be one for the history books. However, there has been an ongoing battle between the bears and the bulls that has kept the price of GILD down; leading to an incredible discount. Nonetheless, after several days of upward movement that I’m convinced will continue, I am a strong believer that the discount mentioned above isn’t likely to last very long. Today, we’ll talk about the reason bears have kicked this stock down every time they could, why bulls absolutely love it, and where the next big climb is likely to start!

Why The Bears Have Taken A Bite Out Of GILD

As mentioned above, Gilead Sciences has traded at a discount for quite some time now. In fact, the stock still trades at a PE ratio that’s below 10. The reason for this is simple. Early this year, AbbVie, Inc. (NYSE: ABBV) received approval for Viekera Pak for the treatment of the hepatitis C virus, Gilead Sciences investors started to get concerned. After all, Gilead Sciences is the world’s leader in the treatment of hepatitis C and with a world-renowned biopharma company stepping in to compete, investors were concerned about GILD’s HCV franchise and its ability to maintain growth. However, those concerns have been put to rest in my opinion.

Gilead Sciences Has Proven Its Strength And Stability

All in all, I think that the tides are changing for Gilead Sciences; and it’s happening in a big way. It all stems from two major events that have happened recently…

  1. Regulatory Approval In Japan – First and foremost, Gilead Sciences recently received regulatory approval in Japan for Harvoni; its hepatitis C medication. This is absolutely huge news considering the fact that the Japanese market is one of the largest in the world; which is likely to lead to incredible profits!
  2. GILD Produced Strong Earnings – Also, a big key investors were looking for was the company’s second quarter earnings report. The reason for this was to see whether or not ABBV really did cut into profits and how badly it affected GILD’s bottom line. However, the earnings report proved that Gilead Sciences has nothing to worry about as the company beat all expectations.

As a result of the strong news above, Gilead Sciences has proven its strength and stability in the hepatitis C space and as a company as a whole. So naturally, we’ve seen strong movement in the market. While I’m expecting to see slow and steady gains in the short term, I think that the gains will increase in momentum when the stock breaks $122.21; where it has met resistance in the past. So, this one will definitely be one to watch moving forward.

What Do You Think?

Where do you think GILD is headed and why? Let us know in the comments below!

Image Credit

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5772
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...